Q32 Bio Q3 net loss $17.6M ($1.46/sh); cash $89.1M; bempikibart Phase 2 AD and AA topline due Dec 2024

Q32 Bio Inc.

2024-Q3 EPS reported -$5.60

Net loss $17.6M vs $14.0M YoY; R&D expense $14.3M (+$6.8M) on clinical costs and $4M milestone to Bristol-Myers Squibb.
Cash $89.1M expected to fund operations into mid-2026 through four Phase 2 milestones.
Bempikibart SIGNAL-AD trial enrolled 121 patients; topline results in AD and AA both expected December 2024.
ADX-097 Phase 2 renal basket enrollment ongoing; initial open-label data 1H’25, topline 2H’25; AAV trial to start 1H’25.
Positive Phase 1 ADX-097 data presented at ASN Kidney Week 2024 supporting Phase 2 dose.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.